Amedeo Smart

Free Medical Literature Service


 

Amedeo

Vaccines

  Free Subscription

Articles published in
Nat Med
    July 2022
  1. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    >> Share

  2. JARA A, Undurraga EA, Zubizarreta JR, Gonzalez C, et al
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.
    Nat Med. 2022;28:1377-1380.
    >> Share

    June 2022
  3. DUCH R, Asiedu E, Nakamura R, Rouyard T, et al
    A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01876.
    >> Share

  4. CAO L, Lou J, Chan SY, Zheng H, et al
    Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.
    Nat Med. 2022 Jun 16. pii: 10.1038/s41591-022-01877.
    >> Share

    May 2022
  5. O'LEARY K
    Finding a vaccine for Epstein-Barr virus.
    Nat Med. 2022 May 19. pii: 10.1038/d41591-022-00061.
    >> Share

  6. MOLINO D, Durier C, Radenne A, Desaint C, et al
    A comparison of Sars-Cov-2 vaccine platforms: the CoviCompare project.
    Nat Med. 2022 May 5. pii: 10.1038/s41591-022-01785.
    >> Share

  7. CHU L, Vrbicky K, Montefiori D, Huang W, et al
    Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Nat Med. 2022;28:1042-1049.
    >> Share

  8. TSENG HF, Ackerson BK, Luo Y, Sy LS, et al
    Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
    Nat Med. 2022;28:1063-1071.
    >> Share

    April 2022
  9. O'LEARY K
    Single vaccine shot protects against cervical cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00056.
    >> Share

  10. ARBEL R, Sergienko R, Friger M, Peretz A, et al
    Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Nat Med. 2022 Apr 25. pii: 10.1038/s41591-022-01832.
    >> Share

  11. PUHACH O, Adea K, Hulo N, Sattonnet P, et al
    Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.
    Nat Med. 2022 Apr 8. pii: 10.1038/s41591-022-01816.
    >> Share

  12. PAJON R, Paila YD, Girard B, Dixon G, et al
    Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
    Nat Med. 2022;28:823-830.
    >> Share

    March 2022
  13. WEBSTER P
    Russian COVID-19 vaccine in jeopardy after Ukraine invasion.
    Nat Med. 2022 Mar 15. pii: 10.1038/d41591-022-00042.
    >> Share

  14. PERTWEE E, Simas C, Larson HJ
    An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.
    Nat Med. 2022 Mar 10. pii: 10.1038/s41591-022-01728.
    >> Share

  15. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    >> Share

  16. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.
    Nat Med. 2022;28:477-480.
    >> Share

  17. GAO Y, Cai C, Grifoni A, Muller TR, et al
    Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
    Nat Med. 2022;28:472-476.
    >> Share

    February 2022
  18. DU Z, Wang L, Pandey A, Lim WW, et al
    Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.
    Nat Med. 2022 Feb 24. pii: 10.1038/s41591-022-01736.
    >> Share

  19. AULADELL M, Phuong HVM, Mai LTQ, Tseng YY, et al
    Influenza virus infection history shapes antibody responses to influenza vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-022-01690.
    >> Share

  20. VALKENBURG SA, Poon LLM
    Exploring the landscape of immune responses to influenza infection and vaccination.
    Nat Med. 2022 Feb 17. pii: 10.1038/s41591-021-01656.
    >> Share

  21. WEI J, Pouwels KB, Stoesser N, Matthews PC, et al
    Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
    Nat Med. 2022 Feb 14. pii: 10.1038/s41591-022-01721.
    >> Share

  22. CERQUEIRA-SILVA T, Katikireddi SV, de Araujo Oliveira V, Flores-Ortiz R, et al
    Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
    Nat Med. 2022 Feb 9. pii: 10.1038/s41591-022-01701.
    >> Share

  23. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Feb 4. pii: 10.1038/s41591-022-01730.
    >> Share

  24. ANDREWS SF, Raab JE, Gorman J, Gillespie RA, et al
    A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01636.
    >> Share

  25. HOUSER KV, Chen GL, Carter C, Crank MC, et al
    Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01660.
    >> Share

    January 2022
  26. WRATIL PR, Stern M, Priller A, Willmann A, et al
    Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
    Nat Med. 2022 Jan 28. pii: 10.1038/s41591-022-01715.
    >> Share

  27. LI J, Hou L, Guo X, Jin P, et al
    Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
    Nat Med. 2022 Jan 27. pii: 10.1038/s41591-021-01677.
    >> Share

  28. PEREZ-THEN E, Lucas C, Monteiro VS, Miric M, et al
    Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01705.
    >> Share

  29. CHENG SMS, Mok CKP, Leung YWY, Ng SS, et al
    Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination.
    Nat Med. 2022 Jan 20. pii: 10.1038/s41591-022-01704.
    >> Share

  30. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
    Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, hospitalisation and death in England.
    Nat Med. 2022 Jan 14. pii: 10.1038/s41591-022-01699.
    >> Share

  31. STOCK SJ, Carruthers J, Calvert C, Denny C, et al
    SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01666.
    >> Share

  32. WARD JK, Gauna F, Gagneux-Brunon A, Botelho-Nevers E, et al
    The French health pass holds lessons for mandatory COVID-19 vaccination.
    Nat Med. 2022 Jan 12. pii: 10.1038/s41591-021-01661.
    >> Share

  33. ETIENNE CF
    COVID-19 has revealed a pandemic of inequality.
    Nat Med. 2022;28:17.
    >> Share

    December 2021
  34. PATONE M, Mei XW, Handunnetthi L, Dixon S, et al
    Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Nat Med. 2021 Dec 14. pii: 10.1038/s41591-021-01630.
    >> Share

  35. ADEPOJU P
    As COVID-19 vaccines arrive in Africa, Omicron is reducing supply and increasing demand.
    Nat Med. 2021 Dec 13. pii: 10.1038/d41591-021-00073.
    >> Share


  36. Vaccine development needs a boost.
    Nat Med. 2021 Dec 2. pii: 10.1038/s41591-021-01633.
    >> Share

  37. O'LEARY K
    A malaria vaccine at last.
    Nat Med. 2021;27:2057.
    >> Share

  38. MORRIS L
    mRNA vaccines offer hope for HIV.
    Nat Med. 2021;27:2082-2084.
    >> Share

  39. ZHANG P, Narayanan E, Liu Q, Tsybovsky Y, et al
    A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
    Nat Med. 2021;27:2234-2245.
    >> Share

  40. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    >> Share

  41. VAN KERKHOVE MD
    COVID-19 in 2022: controlling the pandemic is within our grasp.
    Nat Med. 2021;27:2070.
    >> Share

  42. WEBSTER P
    COVID-19 timeline of events.
    Nat Med. 2021;27:2054-2055.
    >> Share

  43. MAY M
    Eight unanswered questions about the COVID-19 pandemic.
    Nat Med. 2021;27:2058-2061.
    >> Share

  44. ARNOLD C
    11 clinical trials that will shape medicine in 2022.
    Nat Med. 2021;27:2062-2064.
    >> Share

    November 2021
  45. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Nov 29. pii: 10.1038/s41591-021-01644.
    >> Share

  46. O'LEARY K
    An mRNA vaccine against tick bites.
    Nat Med. 2021 Nov 25. pii: 10.1038/d41591-021-00071.
    >> Share

  47. JUNO JA, Wheatley AK
    Boosting immunity to COVID-19 vaccines.
    Nat Med. 2021 Nov 11. pii: 10.1038/s41591-021-01560.
    >> Share

  48. O'LEARY K
    HPV vaccines beat cervical cancer.
    Nat Med. 2021 Nov 11. pii: 10.1038/d41591-021-00068.
    >> Share

  49. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    >> Share

  50. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    >> Share

  51. FENG S, Phillips DJ, White T, Sayal H, et al
    Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:2032-2040.
    >> Share

    October 2021
  52. PATONE M, Handunnetthi L, Saatci D, Pan J, et al
    Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.
    Nat Med. 2021 Oct 25. pii: 10.1038/s41591-021-01556.
    >> Share

  53. POUWELS KB, Pritchard E, Matthews PC, Stoesser N, et al
    Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
    Nat Med. 2021 Oct 14. pii: 10.1038/s41591-021-01548.
    >> Share

  54. ALI M, Khan J, Ahmad N, Khan H, et al
    COVID-19 vaccination gives hope to eradicate polio.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01518.
    >> Share

    September 2021
  55. O'LEARY K
    Low-dose mRNA vaccination measures up.
    Nat Med. 2021 Sep 30. pii: 10.1038/d41591-021-00060.
    >> Share

  56. SHROFF RT, Chalasani P, Wei R, Pennington D, et al
    Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
    Nat Med. 2021 Sep 30. pii: 10.1038/s41591-021-01542.
    >> Share

  57. WILDER-SMITH A, Desai S, Cravioto A, Nohynek H, et al
    Caution before fractionating COVID-19 vaccines.
    Nat Med. 2021 Sep 22. pii: 10.1038/s41591-021-01534.
    >> Share

  58. CHOI A, Koch M, Wu K, Chu L, et al
    Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
    Nat Med. 2021 Sep 15. pii: 10.1038/s41591-021-01527.
    >> Share

  59. APOSTOLIDIS SA, Kakara M, Painter MM, Goel RR, et al
    Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Nat Med. 2021 Sep 14. pii: 10.1038/s41591-021-01507.
    >> Share

  60. DAGAN N, Barda N, Biron-Shental T, Makov-Assif M, et al
    Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
    Nat Med. 2021 Sep 7. pii: 10.1038/s41591-021-01490.
    >> Share

  61. SAVULESCU J, Pugh J, Wilkinson D
    Balancing incentives and disincentives for vaccination in a pandemic.
    Nat Med. 2021 Sep 6. pii: 10.1038/s41591-021-01466.
    >> Share

  62. ONEKO M, Steinhardt LC, Yego R, Wiegand RE, et al
    Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
    Nat Med. 2021;27:1636-1645.
    >> Share

  63. KOUP RA, Donis RO, Gilbert PB, Li AW, et al
    A government-led effort to identify correlates of protection for COVID-19 vaccines.
    Nat Med. 2021;27:1493-1494.
    >> Share

  64. CHOOKAJORN T, Kochakarn T, Wilasang C, Kotanan N, et al
    Southeast Asia is an emerging hotspot for COVID-19.
    Nat Med. 2021;27:1495-1496.
    >> Share

    August 2021
  65. CHAGLA Z, Pai M
    COVID-19 boosters in rich nations will delay vaccines for all.
    Nat Med. 2021 Aug 31. pii: 10.1038/s41591-021-01494.
    >> Share

    July 2021
  66. MEDEIROS-RIBEIRO AC, Aikawa NE, Saad CGS, Yuki EFN, et al
    Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
    Nat Med. 2021 Jul 30. pii: 10.1038/s41591-021-01469.
    >> Share

  67. DEMING ME, Lyke KE
    A 'mix and match' approach to SARS-CoV-2 vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01463.
    >> Share

  68. SCHMIDT T, Klemis V, Schub D, Mihm J, et al
    Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01464.
    >> Share

  69. MACHINGAIDZE S, Wiysonge CS
    Understanding COVID-19 vaccine hesitancy.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.
    >> Share

  70. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
    COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
    >> Share

  71. O'LEARY K
    Another COVID-19 vaccine to boost rollout.
    Nat Med. 2021 Jul 15. pii: 10.1038/d41591-021-00045.
    >> Share

  72. BARROS-MARTINS J, Hammerschmidt SI, Cossmann A, Odak I, et al
    Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Nat Med. 2021 Jul 14. pii: 10.1038/s41591-021-01449.
    >> Share

  73. LOUBET P, Wittkop L, Tartour E, Parfait B, et al
    A French cohort for assessing COVID-19 vaccine responses in specific populations.
    Nat Med. 2021 Jul 12. pii: 10.1038/s41591-021-01435.
    >> Share

  74. CHEMAITELLY H, Yassine HM, Benslimane FM, Al Khatib HA, et al
    mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Nat Med. 2021 Jul 9. pii: 10.1038/s41591-021-01446.
    >> Share

  75. KRAMMER F
    A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
    Nat Med. 2021 Jul 8. pii: 10.1038/s41591-021-01432.
    >> Share

  76. COWLING BJ, Lim WW, Cobey S
    Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01440.
    >> Share

  77. BARBERIA LG, Costa SF, Sabino EC
    Brazil needs a coordinated and cooperative approach to tackle COVID-19.
    Nat Med. 2021;27:1133-1134.
    >> Share

  78. ALOBO M
    Strengthened health systems are needed to tackle COVID-19 in Africa.
    Nat Med. 2021;27:1126-1127.
    >> Share

  79. SINGH J, Rahman SA, Ehtesham NZ, Hira S, et al
    SARS-CoV-2 variants of concern are emerging in India.
    Nat Med. 2021;27:1131-1133.
    >> Share

  80. KHOURY DS, Cromer D, Reynaldi A, Schlub TE, et al
    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:1205-1211.
    >> Share

  81. LUCAS C, Klein J, Sundaram ME, Liu F, et al
    Delayed production of neutralizing antibodies correlates with fatal COVID-19.
    Nat Med. 2021;27:1178-1186.
    >> Share

    June 2021
  82. O'LEARY K
    Building a pandemic-proof vaccine.
    Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.
    >> Share

  83. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    >> Share

  84. KUSTIN T, Harel N, Finkel U, Perchik S, et al
    Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Nat Med. 2021 Jun 14. pii: 10.1038/s41591-021-01413.
    >> Share

  85. MILMAN O, Yelin I, Aharony N, Katz R, et al
    Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
    Nat Med. 2021 Jun 10. pii: 10.1038/s41591-021-01407.
    >> Share

  86. PRITCHARD E, Matthews PC, Stoesser N, Eyre DW, et al
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01410.
    >> Share

  87. PISHKO AM, Bussel JB, Cines DB
    COVID-19 vaccination and immune thrombocytopenia.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01419.
    >> Share

  88. SIMPSON CR, Shi T, Vasileiou E, Katikireddi SV, et al
    First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01408.
    >> Share

  89. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    >> Share


  90. To curb COVID-19, global health must go local.
    Nat Med. 2021;27:929.
    >> Share

    May 2021
  91. MAY M
    After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
    Nat Med. 2021 May 31. pii: 10.1038/s41591-021-01393.
    >> Share

  92. AU L, Fendler A, Shepherd STC, Rzeniewicz K, et al
    Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Nat Med. 2021 May 26. pii: 10.1038/s41591-021-01387.
    >> Share

  93. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2021 May 21. pii: 10.1038/s41591-021-01363.
    >> Share

  94. SCHMIDT H, Weintraub R, Williams MA, Miller K, et al
    Equitable allocation of COVID-19 vaccines in the United States.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01379.
    >> Share

  95. WARD BJ, Gobeil P, Seguin A, Atkins J, et al
    Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01370.
    >> Share

  96. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2021 May 6. pii: 10.1038/s41591-021-01372.
    >> Share

  97. SINGH JA, Kochhar S, Wolff J
    Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 May 4. pii: 10.1038/s41591-021-01360.
    >> Share

  98. ANDREANO E, Rappuoli R
    SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
    Nat Med. 2021;27:759-761.
    >> Share

  99. OTU A, Agogo E, Ebenso B
    Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Nat Med. 2021;27:744-745.
    >> Share

    April 2021

  100. COVID-19 vaccine and blood clotting.
    Nat Med. 2021 Apr 29. pii: 10.1038/d41591-021-00025.
    >> Share

  101. DAL-RE R, Orenstein W, Caplan AL
    Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Nat Med. 2021 Apr 26. pii: 10.1038/s41591-021-01338.
    >> Share

  102. LI J, Hui A, Zhang X, Yang Y, et al
    Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Nat Med. 2021 Apr 22. pii: 10.1038/s41591-021-01330.
    >> Share

  103. ZARD M, Lau LS, Bowser DM, Fouad FM, et al
    Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations.
    Nat Med. 2021 Apr 19. pii: 10.1038/s41591-021-01328.
    >> Share

  104. GIORDANO G, Colaneri M, Di Filippo A, Blanchini F, et al
    Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Nat Med. 2021 Apr 16. pii: 10.1038/s41591-021-01334.
    >> Share

  105. BAUSCH DG
    The need for a new strategy for Ebola vaccination.
    Nat Med. 2021 Apr 5. pii: 10.1038/s41591-021-01313.
    >> Share

  106. EBINGER JE, Fert-Bober J, Printsev I, Wu M, et al
    Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Nat Med. 2021 Apr 1. pii: 10.1038/s41591-021-01325.
    >> Share

  107. EXCLER JL, Saville M, Berkley S, Kim JH, et al
    Vaccine development for emerging infectious diseases.
    Nat Med. 2021;27:591-600.
    >> Share

  108. CHEN RE, Zhang X, Case JB, Winkler ES, et al
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Nat Med. 2021;27:717-726.
    >> Share

  109. WIBMER CK, Ayres F, Hermanus T, Madzivhandila M, et al
    SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Nat Med. 2021;27:622-625.
    >> Share

  110. BURIONI R, Topol EJ
    Assessing the human immune response to SARS-CoV-2 variants.
    Nat Med. 2021;27:571-572.
    >> Share

  111. KINGANDA-LUSAMAKI E, Black A, Mukadi DB, Hadfield J, et al
    Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.
    Nat Med. 2021;27:710-716.
    >> Share

    March 2021
  112. CLARKE PM, Roope LSJ, Loewen PJ, Bonnefon JF, et al
    Public opinion on global rollout of COVID-19 vaccines.
    Nat Med. 2021 Mar 30. pii: 10.1038/s41591-021-01322.
    >> Share

  113. LEVINE-TIEFENBRUN M, Yelin I, Katz R, Herzel E, et al
    Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Nat Med. 2021 Mar 29. pii: 10.1038/s41591-021-01316.
    >> Share

  114. PLANAS D, Bruel T, Grzelak L, Guivel-Benhassine F, et al
    Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Nat Med. 2021 Mar 26. pii: 10.1038/s41591-021-01318.
    >> Share

  115. SARGENT J
    Vaccines reduce childhood mortality.
    Nat Med. 2021 Mar 18. pii: 10.1038/d41591-021-00014.
    >> Share

  116. SINGH JA, Kochhar S, Wolff J
    Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 Mar 16. pii: 10.1038/s41591-021-01299.
    >> Share

  117. EKSTROM AM, Berggren C, Tomson G, Gostin LO, et al
    The battle for COVID-19 vaccines highlights the need for a new global governance mechanism.
    Nat Med. 2021 Mar 11. pii: 10.1038/s41591-021-01288.
    >> Share

  118. MARHOLD K, Fell J
    Electronic vaccination certificates: avoiding a repeat of the contact-tracing 'format wars'.
    Nat Med. 2021 Mar 4. pii: 10.1038/s41591-021-01286.
    >> Share

  119. DURRHEIM DN, Andrus JK, Tabassum S, Bashour H, et al
    A dangerous measles future looms beyond the COVID-19 pandemic.
    Nat Med. 2021;27:360-361.
    >> Share

  120. AHMED I
    Dismantling the anti-vaxx industry.
    Nat Med. 2021;27:366.
    >> Share

    February 2021
  121. VAN DER VELDT AAM, Oosting SF, Dingemans AC, Fehrmann RSN, et al
    COVID-19 vaccination: the VOICE for patients with cancer.
    Nat Med. 2021 Feb 15. pii: 10.1038/s41591-021-01240.
    >> Share

  122. XIE X, Liu Y, Liu J, Zhang X, et al
    Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-021-01270.
    >> Share


  123. COVID-19 vaccines: acting on the evidence.
    Nat Med. 2021 Feb 4. pii: 10.1038/s41591-021-01261.
    >> Share

  124. STOWER H
    A functioning vaccine in mouse models of multiple sclerosis.
    Nat Med. 2021 Feb 1. pii: 10.1038/d41591-021-00006.
    >> Share

    January 2021
  125. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    >> Share

  126. KIM JH, Marks F, Clemens JD
    Looking beyond COVID-19 vaccine phase 3 trials.
    Nat Med. 2021 Jan 19. pii: 10.1038/s41591-021-01230.
    >> Share

  127. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2021 Jan 11. pii: 10.1038/s41591-020-01226.
    >> Share

  128. KAMPMANN B
    Women and children last? Shaking up exclusion criteria for vaccine trials.
    Nat Med. 2021;27:8.
    >> Share

  129. WAGAR LE, Salahudeen A, Constantz CM, Wendel BS, et al
    Modeling human adaptive immune responses with tonsil organoids.
    Nat Med. 2021;27:125-135.
    >> Share

  130. BURTON DR, Topol EJ
    Toward superhuman SARS-CoV-2 immunity?
    Nat Med. 2021;27:5-6.
    >> Share

    December 2020
  131. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01194.
    >> Share

  132. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01179.
    >> Share

  133. NACHBAGAUER R, Feser J, Naficy A, Bernstein DI, et al
    A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nat Med. 2020 Dec 7. pii: 10.1038/s41591-020-1118.
    >> Share

  134. CARVALHO T
    Vaccines in the fast lane.
    Nat Med. 2020;26:1807.
    >> Share

    November 2020
  135. GALLAGHER ME, Sieben AJ, Nelson KN, Kraay ANM, et al
    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Nat Med. 2020 Nov 23. pii: 10.1038/s41591-020-01172.
    >> Share

    October 2020
  136. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2020 Oct 20. pii: 10.1038/s41591-020-1124.
    >> Share


  137. Scientists, keep an open line of communication with the public.
    Nat Med. 2020;26:1495.
    >> Share

    August 2020
  138. PARK JK, Xiao Y, Ramuta MD, Rosas LA, et al
    Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Nat Med. 2020;26:1240-1246.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016